X4 Pharmaceuticals (XFOR) Q3 2024 earnings summary

Executive summary

• FDA approved and launched XOLREMDI (mavorixafor) in the U.S. for WHIM syndrome in April 2024, with EMA submission planned for early 2025 and strong physician engagement and awareness campaigns.

• Positive Phase II results for mavorixafor in chronic neutropenia showed durable ANC increases, good tolerability, and significant G-CSF dose reductions, supporting advancement to the global Phase III 4WARD trial.

• Phase III 4WARD trial for mavorixafor in CN is ongoing, with global site initiation underway and full enrollment expected by mid-2025.

• Sold Priority Review Voucher for $105M, boosting cash position but not expected to recur.

• Company depends almost entirely on XOLREMDI for revenue and faces substantial doubt about its ability to continue as a going concern.

Financial highlights

• Ended Q3 2024 with $135.8 million in cash, cash equivalents, and marketable securities, providing runway into late 2025, not including anticipated XOLREMDI sales ramp-up.

• Net product revenue for Q3 2024 was $0.6 million, with cost of revenue at $0.2 million.

• Net loss for Q3 2024 was $36.7 million, compared to $2.3 million in Q3 2023; nine-month net income of $2.4 million driven by the $105M PRV sale.

• R&D expenses were $19.2 million and SG&A expenses were $15.7 million for Q3 2024, both up year-over-year due to launch costs.

• Accumulated deficit was $475.5 million as of September 30, 2024.

Outlook and guidance

• Sufficient funds projected to support operations into late 2025, excluding future XOLREMDI revenue; additional capital required to fund operations beyond 12 months.

• Phase III 4WARD trial expected to complete enrollment by mid-2025; majority of sites to be initiated by early 2025.

• EMA submission for XOLREMDI in WHIM syndrome planned for early 2025.

• No sales guidance for 2025 provided yet; more commercial insights to be shared as the year progresses.

• Expenses expected to remain consistent in 2025, excluding non-recurring items.